Stocks & Investing
Tue, September 1, 2009Mon, August 31, 2009Sun, August 30, 2009Fri, August 28, 2009Thu, August 27, 2009Wed, August 26, 2009Tue, August 25, 2009Mon, August 24, 2009Sun, August 23, 2009Fri, August 21, 2009Thu, August 20, 2009Wed, August 19, 2009Tue, August 18, 2009Mon, August 17, 2009Fri, August 14, 2009Thu, August 13, 2009Wed, August 12, 2009Tue, August 11, 2009Mon, August 10, 2009Thu, August 6, 2009Wed, August 5, 2009Tue, August 4, 2009Mon, August 3, 2009Sun, August 2, 2009Fri, July 31, 2009Thu, July 30, 2009Wed, July 29, 2009Tue, July 28, 2009Mon, July 27, 2009Fri, July 24, 2009Thu, July 23, 2009Wed, July 22, 2009ChromoCure, Inc.: ChromoCure, Inc. Releases First in Series Business Plan Disclosures and Market Reports
Published in Stocks and Investing on Tuesday, August 4th 2009 at 8:29 GMT, Last Modified on 2009-08-04 08:29:46 by Market Wire
RENO, NV--(Marketwire - August 4, 2009) - ChromoCure, Inc. (
The Company's Business Description and Strategy can be accessed now at the Company's web site: [ http://www.chromocure.com/related-articles/business-plan-dislcosure-set-1/ ]
The disclosure has been properly filed with the OTC Disclosure Service to insure all investors receive timely public information. Investors can access the Company's public filings at [ www.pinksheets.com ] under the Company's "Filings" tab.
Financial Reporting and Regular Disclosures
The Company is completing its full disclosure statement published pursuant to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of Rule 240.15c2-11 and the OTC Disclosure Guidelines. The information filed will be substantially equivalent to the SEC's "Form 10" document. The Company anticipates filing its complete disclosures and financials on 10 August 2009. Upon review by the OTC Disclosure staff, the Company anticipates being issued "Current Information" status.
Investors timely updated on the following:
-- Elimination of all long-term liabilities and removal from the Balance Sheet -- Acquisition of intellectual property, technology, and subsequent patent filings -- Additional appointment to the Company's Advisory and Business Development Boards -- Acquisition of profitable pathology labs to expand the company's operations -- Research and Development agreements with industry partners -- Regular updates and commentary on the Company's proprietary technology and development -- Revenue estimates by industry sector
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic common to all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology is vastly superior to anything in existence and that it will become the undisputed gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's website version of this press release contains various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
